Radioimmunoscintigraphy for colorectal cancer

Current status and future prospects

Research output: Contribution to journalArticle

Abstract

Radioimmunoscintigraphy (RIS) as an imaging modality in oncology is in transition. In early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer, RIS imaged hepatic metastases poorly and immunogenicity was frequent. Technetium-99m-labeled antibody fragments and human MoAbs provide significantly improved imaging efficacy, and lack of immune reactivity makes serial imaging possible. RIS is superior to computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma, and complements CT in imaging liver metastases. In surgical decision-making analyses, RIS improved the accuracy of predicting resectability and nonresectability as compared to CT. New MoAb moieties, manipulation of tumor cell antigen expression, and innovative tumor targeting strategies promise to bring RIS into the mainstream of diagnostic oncology, and, when used in conjunction with intraoperative gamma probes, may allow surgeons to localize and remove disease that can neither be visualized nor palpated.

Original languageEnglish
Pages (from-to)119-126
Number of pages8
JournalSeminars in Colon and Rectal Surgery
Volume13
Issue number2
DOIs
StatePublished - Jun 1 2002

Fingerprint

Radioimmunodetection
Colorectal Neoplasms
Tomography
Monoclonal Antibodies
Neoplasm Metastasis
Immunoglobulin Fragments
Indium
Decision Support Techniques
Liver
Technetium
Neoplasm Antigens
Decision Making
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

Cite this

@article{2fd9253f15104a39b5fcf88e34665b0b,
title = "Radioimmunoscintigraphy for colorectal cancer: Current status and future prospects",
abstract = "Radioimmunoscintigraphy (RIS) as an imaging modality in oncology is in transition. In early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer, RIS imaged hepatic metastases poorly and immunogenicity was frequent. Technetium-99m-labeled antibody fragments and human MoAbs provide significantly improved imaging efficacy, and lack of immune reactivity makes serial imaging possible. RIS is superior to computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma, and complements CT in imaging liver metastases. In surgical decision-making analyses, RIS improved the accuracy of predicting resectability and nonresectability as compared to CT. New MoAb moieties, manipulation of tumor cell antigen expression, and innovative tumor targeting strategies promise to bring RIS into the mainstream of diagnostic oncology, and, when used in conjunction with intraoperative gamma probes, may allow surgeons to localize and remove disease that can neither be visualized nor palpated.",
author = "Moffat, {Frederick L} and Serafini, {Aldo N}",
year = "2002",
month = "6",
day = "1",
doi = "10.1053/scrs.2002.125592",
language = "English",
volume = "13",
pages = "119--126",
journal = "Seminars in Colon and Rectal Surgery",
issn = "1043-1489",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Radioimmunoscintigraphy for colorectal cancer

T2 - Current status and future prospects

AU - Moffat, Frederick L

AU - Serafini, Aldo N

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Radioimmunoscintigraphy (RIS) as an imaging modality in oncology is in transition. In early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer, RIS imaged hepatic metastases poorly and immunogenicity was frequent. Technetium-99m-labeled antibody fragments and human MoAbs provide significantly improved imaging efficacy, and lack of immune reactivity makes serial imaging possible. RIS is superior to computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma, and complements CT in imaging liver metastases. In surgical decision-making analyses, RIS improved the accuracy of predicting resectability and nonresectability as compared to CT. New MoAb moieties, manipulation of tumor cell antigen expression, and innovative tumor targeting strategies promise to bring RIS into the mainstream of diagnostic oncology, and, when used in conjunction with intraoperative gamma probes, may allow surgeons to localize and remove disease that can neither be visualized nor palpated.

AB - Radioimmunoscintigraphy (RIS) as an imaging modality in oncology is in transition. In early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer, RIS imaged hepatic metastases poorly and immunogenicity was frequent. Technetium-99m-labeled antibody fragments and human MoAbs provide significantly improved imaging efficacy, and lack of immune reactivity makes serial imaging possible. RIS is superior to computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma, and complements CT in imaging liver metastases. In surgical decision-making analyses, RIS improved the accuracy of predicting resectability and nonresectability as compared to CT. New MoAb moieties, manipulation of tumor cell antigen expression, and innovative tumor targeting strategies promise to bring RIS into the mainstream of diagnostic oncology, and, when used in conjunction with intraoperative gamma probes, may allow surgeons to localize and remove disease that can neither be visualized nor palpated.

UR - http://www.scopus.com/inward/record.url?scp=0036600408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036600408&partnerID=8YFLogxK

U2 - 10.1053/scrs.2002.125592

DO - 10.1053/scrs.2002.125592

M3 - Article

VL - 13

SP - 119

EP - 126

JO - Seminars in Colon and Rectal Surgery

JF - Seminars in Colon and Rectal Surgery

SN - 1043-1489

IS - 2

ER -